Journal of Advanced Analytics in Healthcare Management

Deep Learning in Personalized Medicine: Advancements and Applications

Katarina Petrovic
Natural science, University of Zadar

Submitted: 13 June 2022
Accepted: 30 November 2022
Published: 02 March 2023

Abstract

Personalized medicine has emerged as a promising approach to healthcare, aiming to provide customized treatment plans based on an individual's unique genetic, environmental, and lifestyle factors. However, the implementation of personalized medicine has been hindered by the vast amount of complex data that needs to be analyzed to make accurate predictions and develop personalized treatment plans. Deep learning, a subset of machine learning that utilizes artificial neural networks, has shown tremendous potential in analyzing complex data and making accurate predictions in various fields, including healthcare. In this study, we explore the potential of deep learning in analyzing genomic data, medical imaging, electronic health records, and drug compounds to advance personalized medicine. The study finds that deep learning models can analyze large amounts of genomic data, medical imaging, electronic health records, and drug compounds to predict disease risk, diagnose diseases, suggest personalized treatment plans, and develop new drugs. Specifically, the study reveals that deep learning algorithms can identify genetic markers associated with specific diseases or drug responses from genomic data, detect abnormalities and diagnose diseases from medical imaging, predict disease risk and suggest personalized treatment plans from electronic health records, and predict the efficacy and toxicity of drug compounds. These findings suggest that the integration of deep learning into clinical practice could lead to more accurate diagnoses, personalized treatment plans, and improved patient outcomes.

Keywords: *Personalized Medicine, Deep Learning, Genomic Data, Medical Imaging, Drug Compounds*

Introduction

Deep learning is a subfield of machine learning that involves the use of artificial neural networks to enable machines to learn from large amounts of data. These neural networks consist of multiple layers of interconnected nodes, with each layer learning to recognize increasingly complex features of the input data. Deep learning has been shown to be particularly effective in tasks such as image recognition, natural language processing, and speech recognition.

One of the key advantages of deep learning is its ability to learn representations of data automatically. Traditionally, machine learning algorithms required engineers to manually design features that could be extracted from the data and used to train the model. With deep learning, the model learns these features on its own through a process known as feature learning. This makes it possible to train deep learning models on very large datasets without the need for manual feature engineering, allowing for much more complex and accurate models.

Another advantage of deep learning is its ability to generalize well to new data. Deep learning models are designed to identify patterns in data, and can often perform well even when faced with data that is different from the data it was trained on. This makes deep learning particularly useful in applications where the input data is likely to be diverse and unpredictable, such as speech recognition or object recognition.

Figure 1. AI/ML modeling in medicine (Gercia and Lemus)



Despite its many advantages, deep learning is not without its challenges. One of the main challenges is the need for large amounts of labeled data to train the models. This is particularly challenging in fields such as healthcare or finance, where labeled data may be scarce or expensive to obtain. Additionally, deep learning models can be computationally expensive to train and may require specialized hardware such as GPUs or TPUs to achieve optimal performance.

Deep learning has revolutionized the field of machine learning and has enabled significant advancements in areas such as computer vision, natural language processing, and speech recognition. Its ability to learn complex representations of data automatically and to generalize well to new data make it a powerful tool for solving a wide range of real-world problems. However, deep learning also presents challenges such as the need for large amounts of labeled data and the computational resources required to train models, and ongoing research is needed to address these challenges and continue to advance the field.

Deep learning has the potential to revolutionize personalized medicine by allowing for more accurate diagnoses and targeted treatment plans. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, such as their genetics, medical history, and lifestyle. Deep learning algorithms can be trained on large amounts of patient data, including genomic data, medical imaging, and clinical records, to identify patterns and make predictions about individual patient outcomes.

integrating data in precision medicine for AI/ML modeling involves several steps. Firstly, since there are numerous data sources with different features, various methods for collecting and pre-processing the data are required. Secondly, integrating these heterogeneous data sources is a significant challenge for the effective application of AI/ML approaches to precision medicine. However, overcoming these challenges will lead to significant advancements in the field of precision medicine.

The proposed workflow highlights the challenges associated with integrating heterogeneous data sources in precision medicine for AI/ML modeling. With the increasing availability of data from various sources, there is a need for different methods of data collection and pre-processing. This is because the data may be diverse and may require different approaches for effective integration. The integration of these diverse data sources is essential for the effective application of AI/ML approaches in precision medicine. However, the integration of such heterogeneous data is a significant challenge. Overcoming this challenge will lead to significant improvements in precision medicine, such as personalized treatment and more accurate diagnoses. Therefore, it is crucial to develop effective methods for integrating heterogeneous data sources to ensure the success of AI/ML modeling in precision medicine.

One area where deep learning is already making a significant impact is in the field of cancer diagnosis and treatment. By analyzing genomic data, deep learning algorithms can identify the specific genetic mutations that are driving a patient's cancer and predict which treatments are likely to be most effective. This can lead to more targeted and personalized treatment plans that are tailored to the specific characteristics of each patient's cancer. Additionally, deep learning can be used to analyze medical imaging data, such as MRI or CT scans, to identify early signs of cancer or to monitor the effectiveness of treatment over time.

Another area where deep learning is showing promise is in predicting patient outcomes and identifying high-risk patients. By analyzing large amounts of patient data, including clinical records and medical imaging, deep learning algorithms can identify patterns that are predictive of disease progression or treatment response. This can help doctors to identify high-risk patients who may benefit from more aggressive treatment or closer monitoring, as well as to predict which patients are likely to respond well to a particular treatment.

However, there are also challenges to using deep learning in personalized medicine. One major challenge is the need for large amounts of high-quality data to train the algorithms. This is particularly challenging in the case of rare diseases or rare genetic mutations, where there may be limited data available. Additionally, there are concerns about the potential for bias in the data used to train the algorithms, which could lead to inaccurate predictions or unequal treatment of different patient populations.

Overall, deep learning has the potential to transform personalized medicine by enabling more accurate diagnoses, targeted treatment plans, and improved patient outcomes. While there are challenges to using deep learning in this field, ongoing research is focused on addressing these challenges and unlocking the full potential of this powerful technology.

Genomics:

Genomics is the study of the genetic information of living organisms. In recent years, advances in sequencing technology have made it possible to generate vast amounts of genomic data. However, analyzing this data to extract meaningful insights can be challenging, as genomic data is highly complex and can involve thousands of variables. Deep learning algorithms have emerged as a powerful tool for analyzing genomic data and predicting disease risk.

One area where deep learning is showing promise in genomics is in identifying genetic markers that are associated with specific diseases or drug responses. By analyzing large amounts of genomic data, deep learning algorithms can identify patterns that are predictive of disease risk or treatment response. For example, deep learning models can be trained to identify genetic variants that are associated with an increased risk of developing certain cancers or other diseases. This information can be used to develop personalized treatment plans that are tailored to the specific genetic characteristics of each patient.

Another area where deep learning is making an impact in genomics is in the field of gene expression analysis. Gene expression refers to the process by which information encoded in DNA is used to create proteins that perform various functions in the body. By analyzing gene expression data, deep learning algorithms can identify patterns that are predictive of disease progression or response to treatment. This information can be used to develop personalized treatment plans that target the specific genes or proteins that are driving a patient's disease.

Despite its many advantages, there are also challenges to using deep learning in genomics. One of the biggest challenges is the need for large amounts of high-quality data to train the algorithms. Additionally, there are concerns about the potential for bias in the data used to train the algorithms, which could lead to inaccurate predictions or unequal treatment of different patient populations.

Deep learning is a powerful tool for analyzing genomic data and has the potential to revolutionize personalized medicine. By identifying genetic markers that are associated with specific diseases or drug responses, deep learning can enable more targeted and personalized treatment plans that are tailored to the specific genetic characteristics of each patient. While there are challenges to using deep learning in genomics, ongoing research is focused on addressing these challenges and unlocking the full potential of this powerful technology.

Medical imaging:

Medical imaging is an essential tool for diagnosing and monitoring a wide range of diseases and conditions. However, interpreting medical images can be time-consuming and challenging, as abnormalities can be subtle and difficult to detect. Deep learning algorithms have emerged as a powerful tool for analyzing medical images and detecting abnormalities that might be missed by human clinicians.

Deep learning algorithms can be trained on large datasets of medical images, such as CT scans, MRIs, and X-rays, to detect abnormalities and diagnose diseases. For example, deep learning algorithms can be trained to identify early signs of cancer on mammograms or to detect subtle changes in brain imaging that might indicate the presence of a neurodegenerative disease such as Alzheimer's. By analyzing large amounts of medical imaging data, deep learning algorithms can identify patterns that are predictive of disease progression or treatment response, enabling more personalized treatment plans.

One of the advantages of deep learning in medical imaging is that it can analyze images more quickly and accurately than human clinicians. This can help doctors make more accurate and timely diagnoses, which can be critical in cases where early detection and treatment can make a significant difference in patient outcomes. Additionally, deep learning algorithms can be used to analyze medical images in real-time, which can be particularly useful in emergency settings where time is of the essence.

Despite its many advantages, there are also challenges to using deep learning in medical imaging. One of the biggest challenges is the need for large amounts of high-quality data to train the algorithms. Additionally, there are concerns about the potential for bias in the data used to train the algorithms, which could lead to inaccurate predictions or unequal treatment of different patient populations.

In conclusion, deep learning is a powerful tool for analyzing medical images and has the potential to transform the field of medical imaging and diagnosis. By detecting abnormalities that might be missed by human clinicians and enabling more personalized treatment plans, deep learning can improve patient outcomes and save lives. While there are challenges to using deep learning in medical imaging, ongoing research is focused on addressing these challenges and unlocking the full potential of this powerful technology.

Electronic health records:

Electronic health records (EHRs) have become an increasingly important tool for managing patient care in modern healthcare systems. EHRs contain a wealth of patient data, including medical histories, diagnostic test results, and treatment plans. Deep learning models can be trained on this data to predict disease risk, identify patients who are at risk of developing specific conditions, and suggest personalized treatment plans.

One area where deep learning is making an impact in EHRs is in predicting disease risk. By analyzing large amounts of patient data, deep learning algorithms can identify patterns that are predictive of disease risk. For example, deep learning models can be trained to identify patients who are at high risk of developing cardiovascular disease based on factors such as age, family history, and lifestyle factors. This information can be used to develop targeted interventions to help prevent the development of the disease.

Another area where deep learning is showing promise in EHRs is in identifying patients who are at risk of developing specific conditions. By analyzing patient data, deep learning algorithms can identify patients who are at high risk of developing conditions such as diabetes, cancer, or neurodegenerative diseases such as Alzheimer's. This information can be used to develop personalized treatment plans that are tailored to the specific needs of each patient, helping to reduce the risk of adverse events and improve patient outcomes.

Despite its many advantages, there are also challenges to using deep learning in EHRs. One of the biggest challenges is the need for large amounts of high-quality data to train the algorithms. Additionally, there are concerns about the potential for bias in the data used to train the algorithms, which could lead to inaccurate predictions or unequal treatment of different patient populations.

In conclusion, deep learning is a powerful tool for analyzing EHRs and has the potential to transform the way healthcare is delivered. By predicting disease risk, identifying patients who are at risk of developing specific conditions, and suggesting personalized treatment plans, deep learning can enable more targeted and effective interventions, reduce the risk of adverse events, and improve patient outcomes. While there are challenges to using deep learning in EHRs, ongoing research is focused on addressing these challenges and unlocking the full potential of this powerful technology.

Drug discovery:

Drug discovery is a time-consuming and costly process that involves screening large numbers of drug compounds to identify those that are effective and safe. Deep learning algorithms have emerged as a powerful tool for drug discovery, as they can be trained on large datasets of drug compounds to predict their efficacy and toxicity. By analyzing large amounts of data, deep learning algorithms can identify patterns and relationships that might be missed by human researchers, enabling more effective and efficient drug discovery.

One area where deep learning is making an impact in drug discovery is in predicting drug efficacy. By analyzing large datasets of drug compounds and their effects on biological systems, deep learning algorithms can identify patterns and relationships that can help predict how well a drug will work. For example, deep learning models can be trained to predict how effective a cancer drug will be based on the specific genetic mutations present in a patient's tumor. This information can be used to develop more personalized treatment plans that are tailored to the individual needs of each patient.

Another area where deep learning is showing promise in drug discovery is in predicting drug toxicity. By analyzing large datasets of drug compounds and their effects on biological systems, deep learning algorithms can identify patterns and relationships that can help predict how toxic a drug will be. This information can be used to identify potentially harmful drugs early in the drug discovery process and reduce the risk of adverse events.

Despite its many advantages, there are also challenges to using deep learning in drug discovery. One of the biggest challenges is the need for large amounts of high-quality data to train the algorithms. Additionally, there are concerns about the potential for bias in the data used to train the algorithms, which could lead to inaccurate predictions or unequal treatment of different patient populations. Deep learning is a powerful tool for drug discovery and has the potential to transform the way new drugs are developed and personalized treatment plans are developed. By predicting drug efficacy and toxicity, deep learning can enable more effective and efficient drug discovery, reduce the risk of adverse events, and improve patient outcomes. While there are challenges to using deep learning in drug discovery, ongoing research is focused on addressing these challenges and unlocking the full potential of this powerful technology.

Conclusion

Deep learning is a subset of artificial intelligence that uses artificial neural networks with multiple layers to analyze data and recognize patterns. With the increasing availability of big data in healthcare, deep learning has the potential to transform personalized medicine by enabling doctors to provide more accurate diagnoses and develop personalized treatment plans based on a patient's individual characteristics. By analyzing large amounts of patient data, deep learning algorithms can identify hidden patterns and relationships that are not immediately apparent to human clinicians. This allows doctors to make more informed decisions and provide better care for their patients. For example, deep learning algorithms can analyze medical images to detect cancerous cells or abnormal growths, and predict the likelihood of a disease recurrence.

However, it's important to note that deep learning algorithms require large amounts of data to be effective. In healthcare, this data comes from various sources such as electronic health records, medical images, genomic data, and wearables. Collecting and integrating these data sources can be challenging, as they may be fragmented across different systems and formats. Moreover, data privacy and security are major concerns in healthcare, as patient data must be kept confidential and protected from cyber threats. Deep learning algorithms are only as effective as the data they are trained on, and bias in the data can lead to biased or inaccurate results. Therefore, it's important to address these challenges to ensure that deep learning can be widely adopted in healthcare.

Personalized medicine can help to reduce healthcare costs by optimizing treatment plans, reducing hospital readmissions, and improving patient outcomes. Deep learning can also help to identify new drug targets and accelerate drug development by predicting the efficacy and safety of potential drugs. In addition, deep learning can help to improve healthcare operations by predicting patient flow and resource utilization, and identifying areas for process improvement. These benefits demonstrate the potential of deep learning to transform healthcare and improve patient outcomes.

Deep learning has the potential to transform personalized medicine in healthcare by enabling doctors to provide more accurate diagnoses and develop personalized treatment plans based on a patient's individual characteristics. However, deep learning algorithms require large amounts of data to be effective, and there are still many challenges to overcome, such as data privacy and bias, before deep learning can be widely adopted in healthcare. Despite these challenges, the potential benefits of deep learning in healthcare are significant, and it's important to continue to develop and improve deep learning algorithms to ensure that they can be used effectively and responsibly in healthcare.

References

[1] D. Learning, "Deep learning," *High-dimensional fuzzy clustering*, 2020.

[2] Y. LeCun, Y. Bengio, and G. Hinton, "Deep learning," *Nature*, vol. 521, no. 7553, pp. 436–444, May 2015.

[3] A. S. W. Chan, "Book Review: Safe Is Not Enough: Better Schools for LGBTQ Students (Youth Development and Education Series)," 2021.

[4] A. S. W. Chan, P. M. K. Tang, and E. Yan, "Chemsex and its risk factors associated with human immunodeficiency virus among men who have sex with men in Hong Kong," *World Journal of Virology*, 2022.

[5] L. C. Yan, B. Yoshua, and H. Geoffrey, "Deep learning," *Nature*, vol. 521, no. 7553, pp. 436–444, 2015.

[6] A. Kamilaris and F. X. Prenafeta-Boldú, "Deep learning in agriculture: A survey," *Comput. Electron. Agric.*, vol. 147, pp. 70–90, Apr. 2018.

[7] A. S. W. Chan *et al.*, "Impacts of psychological wellbeing with HIV/AIDS and cancer among sexual and gender minorities: A systematic review and meta-analysis," *Front Public Health*, vol. 10, p. 912980, Nov. 2022.

[8] A. S. W. Chan, J. S. F. Li, J. M. C. Ho, H. L. Tam, and W. L. Hsu, "The systematic review and meta-analysis of Chronic Inflammation and Fibrosis in HIV/AIDS and Cancer: Impacts of Psychological Wellbeing among …," *Frontiers in Public*.

[9] A. S. W. Chan, "Book review: the Educator's guide to LGBT+ inclusion: a practical resource for K-12 teachers, administrators, and school support staff," 2021.

[10] P. Uyyala, "COLLUSION DEFENDER PRESERVING SUBSCRIBERS PRIVACY IN PUBLISH AND SUBSCRIBE SYSTEMS," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 4, pp. 2639–2645, 2021.

[11] A. S. W. Chan, "Book review: the deviant's war: the homosexual vs. the United States of America," 2021.

[12] L. Deng and D. Yu, "Deep Learning: Methods and Applications," *Found. Signal. Process. Commun. Netw.*, vol. 7, no. 3–4, pp. 197–387, 2014.

[13] L. H. Goetz and N. J. Schork, "Personalized medicine: motivation, challenges, and progress," *Fertil. Steril.*, vol. 109, no. 6, pp. 952–963, Jun. 2018.

[14] A. S. W. Chan and Others, "Safe is not enough: better schools for LGBTQ students (youth development and education series)[Book review]," 2021.

[15] A. S. W. Chan, J. M. C. Ho, H. L. Tam, W. L. Hsu, and P. M. K. Tang, "COVID-19, SARS, and MERS: the risk factor associated with depression and its impact on psychological well-being among sexual moralities," 2022.

[16] H. L. Tam, L. Y. L. Leung, and E. M. L. Wong, "Integration of text messaging interventions into hypertension management among older adults: a systematic review and meta-analysis," *on Evidence-Based …*, 2022.

[17] M. Livne *et al.*, "A U-net deep learning framework for high performance vessel segmentation in patients with cerebrovascular disease," *Front. Neurosci.*, vol. 13, p. 97, Feb. 2019.

[18] V. W. Xue *et al.*, "USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages," *Mol Ther Oncolytics*, vol. 23, pp. 26–37, Dec. 2021.

[19] J. Y. F. Chung, M. K. K. Chan, and P. C. T. Tang, "AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma," *Journal of Cellular*, 2021.

[20] F. Q. Lauzon, "An introduction to deep learning," *2012 11th international conference on information*, 2012.

[21] T. W. Smith and S. A. Colby, "Teaching for Deep Learning," *The Clearing House: A Journal of Educational Strategies, Issues and Ideas*, vol. 80, no. 5, pp. 205–210, May 2007.

[22] Z. Qi, B. Wang, Y. Tian, and P. Zhang, "When Ensemble Learning Meets Deep Learning: a New Deep Support Vector Machine for Classification," *Knowledge-Based Systems*, vol. 107, pp. 54–60, Sep. 2016.

[23] N. Polyzos, S. Karakolias, G. Mavridoglou, P. Gkorezis, and C. Zilidis, "Current and future insight into human resources for health in Greece," *Open J. Soc. Sci.*, vol. 03, no. 05, pp. 5–14, 2015.

[24] N. Rusk, "Deep learning," *Nat. Methods*, vol. 13, no. 1, pp. 35–35, Dec. 2015.

[25] P. Uyyala, "SECURE CRYPTO-BIOMETRIC SYSTEM FOR CLOUD COMPUTING," *Journal of interdisciplinary cycle research*, vol. 14, no. 6, pp. 2344–2352, 2022.

[26] R. L. Schilsky, "Personalized medicine in oncology: the future is now," *Nat. Rev. Drug Discov.*, vol. 9, no. 5, pp. 363–366, May 2010.

[27] P. Uyyala, "Efficient and Deployable Click Fraud Detection for Mobile Applications," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 1, pp. 2360–2372, 2021.

[28] E. Abrahams and M. Silver, "The case for personalized medicine," *J. Diabetes Sci. Technol.*, vol. 3, no. 4, pp. 680–684, Jul. 2009.

[29] S. H. Katsanis, G. Javitt, and K. Hudson, "A case study of personalized medicine," *Science*, 2008.

[30] P. Uyyala, "Secure Channel Free Certificate-Based Searchable Encryption Withstanding Outside and Inside Keyword Guessing Attacks," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 2, pp. 2467–2474, 2021.
[31] C. Janiesch, P. Zschech, and K. Heinrich, "Machine learning and deep learning," *Electronic Markets*, vol. 31, no. 3, pp. 685–695, Sep. 2021.
[32] M. Verma, "Personalized medicine and cancer," *J Pers Med*, vol. 2, no. 1, pp. 1–14, Jan. 2012.
[33] P. Uyyala, "Delegated Authorization Framework for EHR Services using Attribute Based Encryption," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 3, pp. 2447–2451, 2021.
[34] K. K. Jain, *Textbook of Personalized Medicine*. Cham, Switzerland: Springer Nature, 2020.
[35] P. Uyyala, "Credit Card Transactions Data Adversarial Augmentation in the Frequency Domain," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 5, pp. 2712–2718, 2021.
[36] G. H. Fernald, E. Capriotti, and R. Daneshjou, "Bioinformatics challenges for personalized medicine," 2011.
[37] P. Uyyala, "Privacy-aware Personal Data Storage (P-PDS): Learning how toProtect User Privacy from External Applications," *The International journal of analytical and experimental modal analysis*, vol. 13, no. 6, pp. 3257–3273, 2021.
[38] S. Senn, "Statistical pitfalls of personalized medicine," *Nature*, vol. 563, no. 7733, pp. 619–621, Nov. 2018.
[39] A. Gulli and S. Pal, "Deep learning with Keras," 2017.
[40] A. Mathew, P. Amudha, and S. Sivakumari, "Deep Learning Techniques: An Overview," in *Advanced Machine Learning Technologies and Applications*, 2021, pp. 599–608.
[41] J. R. Everett, R. L. Loo, and F. S. Pullen, "Pharmacometabonomics and personalized medicine," *Ann. Clin. Biochem.*, vol. 50, no. Pt 6, pp. 523–545, Nov. 2013.
[42] P. Uyyala, "SIGN LANGUAGE RECOGNITION USING CONVOLUTIONAL NEURAL NETWORKS," *Journal of interdisciplinary cycle research*, vol. 14, no. 1, pp. 1198–1207, 2022.
[43] X. Hao, G. Zhang, and S. Ma, "Deep learning," *Int. J. Semant. Comput.*, 2016.
[44] K. Offit, "Personalized medicine: new genomics, old lessons," *Hum. Genet.*, vol. 130, no. 1, pp. 3–14, Jul. 2011.
[45] P. Uyyala, "PREDICTING RAINFALL USING MACHINE LEARNING TECHNIQUES," *J. Interdiscipl. Cycle Res.*, vol. 14, no. 2, pp. 1284–1292, 2022.

[46] S. Nikolenko, A. Kadurin, and E. Arkhangelskaya, “Deep learning,” *SPb.: Peter*, 2018.
[47] J. Schmidhuber, “Deep learning,” *Scholarpedia J.*, 2015.
[48] E. Stevens, L. Antiga, and T. Viehmann, “Deep learning with PyTorch,” 2020.
[49] P. Uyyala, “DETECTION OF CYBER ATTACK IN NETWORK USING MACHINE LEARNING TECHNIQUES,” *Journal of interdisciplinary cycle research*, vol. 14, no. 3, pp. 1903–1913, 2022.
[50] M. Denil, B. Shakibi, L. Dinh, M. Ranzato, and N. De Freitas, “Predicting parameters in deep learning,” *Adv. Neural Inf. Process. Syst.*, vol. 26, 2013.
[51] P. Uyyala, “DETECTING AND CHARACTERIZING EXTREMIST REVIEWER GROUPS IN ONLINE PRODUCT REVIEWS,” *Journal of interdisciplinary cycle research*, vol. 14, no. 4, pp. 1689–1699, 2022.
[52] I. Goodfellow, Y. Bengio, and A. Courville, *Deep Learning*. London, England: MIT Press, 2016.
[53] P. Uyyala, “AUTOMATIC DETECTION OF GENETIC DISEASES IN PEDIATRIC AGE USING PUPILLOMETRY,” *Journal of interdisciplinary cycle research*, vol. 14, no. 5, pp. 1748–1760, 2022.
[54] M. Martínez-García and E. Hernández-Lemus, “Data Integration Challenges for Machine Learning in Precision Medicine,” *Front. Med.*, vol. 8, p. 784455, 2021.
[55] U. Varshney, *Pervasive healthcare computing: EMR/EHR, wireless and health monitoring*, 2009th ed. New York, NY: Springer, 2009.
[56] T. Stepurko, M. Pavlova, and W. Groot, “Overall satisfaction of health care users with the quality of and access to health care services: a cross-sectional study in six Central and Eastern European …,” *BMC Health Serv. Res.*, 2016.
[57] S. Conard, “Best practices in digital health literacy,” *Int. J. Cardiol.*, 2019.
[58] R. D. Beger, “Cambridge Healthtech Institute’s 7th Annual, identifying and validating metabolic markers for drug development and clinical studies,” *Expert Rev. Mol. Diagn.*, vol. 7, no. 2, pp. 113–115, Mar. 2007.
[59] P. Hamet and J. Tremblay, “Artificial intelligence in medicine,” *Metabolism*, 2017.
[60] S. Karakolias and C. Kastanioti, “Application of an organizational assessment tool of primary health care,” *Arch Hell Med*, vol. 35, pp. 497–505, 2018.
[61] A. M. Issa, “Personalized medicine and the practice of medicine in the 21st century,” *Mcgill J. Med.*, vol. 10, no. 1, pp. 53–57, Jan. 2007.

[62] M. Whirl-Carrillo *et al.*, "Pharmacogenomics knowledge for personalized medicine," *Clin. Pharmacol. Ther.*, vol. 92, no. 4, pp. 414–417, Oct. 2012.
[63] S. Mathur and J. Sutton, "Personalized medicine could transform healthcare," *Biomed Rep*, vol. 7, no. 1, pp. 3–5, Jul. 2017.
[64] S. Jakka and M. Rossbach, "An economic perspective on personalized medicine," *Hugo J.*, vol. 7, no. 1, pp. 1–6, Apr. 2013.
[65] N. J. Schork, "Artificial Intelligence and Personalized Medicine," *Cancer Treat. Res.*, vol. 178, pp. 265–283, 2019.
[66] S. Bates, "Progress towards personalized medicine," *Drug Discov. Today*, vol. 15, no. 3–4, pp. 115–120, Feb. 2010.
[67] K. K. Jain, "Role of pharmacoproteomics in the development of personalized medicine," *Pharmacogenomics*, vol. 5, no. 3, pp. 331–336, Apr. 2004.
[68] D. C. Whitcomb, "What is personalized medicine and what should it replace?," *Nat. Rev. Gastroenterol. Hepatol.*, vol. 9, no. 7, pp. 418–424, May 2012.
[69] W. Burke and B. M. Psaty, "Personalized medicine in the era of genomics," *JAMA*, vol. 298, no. 14, pp. 1682–1684, Oct. 2007.
[70] A. Alyass, M. Turcotte, and D. Meyre, "From big data analysis to personalized medicine for all: challenges and opportunities," *BMC Med. Genomics*, vol. 8, no. 1, pp. 1–12, Jun. 2015.
[71] E.-C. Kim, E.-Y. Kim, H.-C. Lee, and B.-J. Yoo, "The Details and Outlook of Three Data Acts Amendment in South Korea: With a Focus on the Changes of Domestic Financial and Data Industry," *Informatization Policy*, vol. 28, no. 3, pp. 49–72, 2021.
[72] A. Rajkomar *et al.*, "Scalable and accurate deep learning with electronic health records," *NPJ Digit Med*, vol. 1, p. 18, May 2018.
[73] E. Kim, J. Kim, J. Park, H. Ko, and Y. Kyung, "TinyML-Based Classification in an ECG Monitoring Embedded System," *CMC-COMPUTERS MATERIALS & CONTINUA*, vol. 75, no. 1, pp. 1751–1764, 2023.
[74] Z. Liang, G. Zhang, J. X. Huang, and Q. V. Hu, "Deep learning for healthcare decision making with EMRs," in *2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, 2014, pp. 556–559.
[75] M. Rana and M. Bhushan, "Advancements in healthcare services using deep learning techniques," *2022 International Mobile and*, 2022.
[76] E. Kim, M. Kim, and Y. Kyung, "A Case Study of Digital Transformation: Focusing on the Financial Sector in South Korea and Overseas," *Asia Pacific Journal of Information Systems*, vol. 32, no. 3, pp. 537–563, 2022.
[77] D. Ravì *et al.*, "Deep Learning for Health Informatics," *IEEE Journal of Biomedical and Health Informatics*, vol. 21, no. 1, pp. 4–21, Jan. 2017.

[78] A. S. W. Chan, D. Wu, I. P. Y. Lo, J. M. C. Ho, and E. Yan, “Diversity and Inclusion: Impacts on Psychological Wellbeing Among Lesbian, Gay, Bisexual, Transgender, and Queer Communities,” *Front. Psychol.*, vol. 13, p. 726343, Apr. 2022.
[79] H. Su and X. Zhang, “Battery-dynamics driven tdma mac protocols for wireless body-area monitoring networks in healthcare applications,” *IEEE J. Sel. Areas Commun.*, vol. 27, no. 4, pp. 424–434, May 2009.
[80] S. Durga, R. Nag, and E. Daniel, “Survey on Machine Learning and Deep Learning Algorithms used in Internet of Things (IoT) Healthcare,” in *2019 3rd International Conference on Computing Methodologies and Communication (ICCMC)*, 2019, pp. 1018–1022.
[81] A. A. Abdullah, M. M. Hassan, and Y. T. Mustafa, “A Review on Bayesian Deep Learning in Healthcare: Applications and Challenges,” *IEEE Access*, vol. 10, pp. 36538–36562, 2022.
[82] B. Choi, Y. Lee, Y. Kyung, and E. Kim, “ALBERT with Knowledge Graph Encoder Utilizing Semantic Similarity for Commonsense Question Answering,” *arXiv [cs.CL]*, 14-Nov-2022.
[83] D. Kaul, H. Raju, and B. K. Tripathy, “Deep Learning in Healthcare,” in *Deep Learning in Data Analytics: Recent Techniques, Practices and Applications*, D. P. Acharjya, A. Mitra, and N. Zaman, Eds. Cham: Springer International Publishing, 2022, pp. 97–115.
[84] A. S. W. Chan, “Book review: the gay revolution: the story of the struggle,” 2021.
[85] E. Kim *et al.*, “SHOMY: Detection of Small Hazardous Objects using the You Only Look Once Algorithm,” *KSII Transactions on Internet & Information Systems*, vol. 16, no. 8, 2022.
[86] Y. W. Chen and L. C. Jain, *Deep learning in healthcare: Paradigms and applications*, 1st ed. Cham, Switzerland: Springer Nature, 2019.
[87] R. Miotto, F. Wang, S. Wang, X. Jiang, and J. T. Dudley, “Deep learning for healthcare: review, opportunities and challenges,” *Brief. Bioinform.*, vol. 19, no. 6, pp. 1236–1246, Nov. 2018.
[88] E. Kim, Y. Lee, J. Choi, B. Yoo, K. J. Chae, and C. H. Lee, “Machine Learning-based Prediction of Relative Regional Air Volume Change from Healthy Human Lung CTs,” *KSII Transactions on Internet & Information Systems*, vol. 17, no. 2, 2023.
[89] O. Faust, Y. Hagiwara, T. J. Hong, O. S. Lih, and U. R. Acharya, “Deep learning for healthcare applications based on physiological signals: A review,” *Comput. Methods Programs Biomed.*, vol. 161, pp. 1–13, Jul. 2018.
[90] N. Polyzos *et al.*, “The introduction of Greek Central Health Fund: Has the reform met its goal in the sector of Primary Health Care or

is there a new model needed?," *BMC Health Serv. Res.*, vol. 14, p. 583, Nov. 2014.

[91] M. G. Aspinall and R. G. Hamermesh, "Realizing the promise of personalized medicine," *Harv. Bus. Rev.*, vol. 85, no. 10, pp. 108–17, 165, Oct. 2007.

[92] S. Mittal and Y. Hasija, "Applications of Deep Learning in Healthcare and Biomedicine," in *Deep Learning Techniques for Biomedical and Health Informatics*, S. Dash, B. R. Acharya, M. Mittal, A. Abraham, and A. Kelemen, Eds. Cham: Springer International Publishing, 2020, pp. 57–77.

[93] P. Bhattacharya, S. Tanwar, U. Bodkhe, S. Tyagi, and N. Kumar, "BinDaaS: Blockchain-based deep-learning as-a-service in healthcare 4.0 applications," *IEEE Trans. Netw. Sci. Eng.*, vol. 8, no. 2, pp. 1242–1255, Apr. 2021.

[94] A. S. W. Chan, I. P. Y. Lo, and E. Yan, "Health and Social Inclusion: The Impact of Psychological Well-Being and Suicide Attempts Among Older Men Who Have Sex With Men," *Am. J. Mens. Health*, vol. 16, no. 5, p. 15579883221120984, Sep-Oct 2022.

[95] O. Stephen, M. Sain, U. J. Maduh, and D.-U. Jeong, "An Efficient Deep Learning Approach to Pneumonia Classification in Healthcare," *J. Healthc. Eng.*, vol. 2019, p. 4180949, Mar. 2019.

[96] A. S. W. Chan, J. M. C. Ho, J. S. F. Li, and H. L. Tam, "Impacts of COVID-19 pandemic on psychological well-being of older chronic kidney disease patients," *Frontiers in Medicine*, 2021.

[97] B. Norgeot, B. S. Glicksberg, and A. J. Butte, "A call for deep-learning healthcare," *Nat. Med.*, vol. 25, no. 1, pp. 14–15, Jan. 2019.

[98] A. S. W. Chan, J. M. C. Ho, H. L. Tam, and P. M. K. Tang, "Book review: successful aging: a neuroscientist explores the power and potential of our lives," *Front. Psychol.*, 2021.

[99] S. Purushotham, C. Meng, Z. Che, and Y. Liu, "Benchmarking deep learning models on large healthcare datasets," *J. Biomed. Inform.*, vol. 83, pp. 112–134, Jul. 2018.

[100] E. Kim and Y. Kyung, "Factors Affecting the Adoption Intention of New Electronic Authentication Services: A Convergent Model Approach of VAM, PMT, and TPB," *IEEE Access*, vol. 11, pp. 13859–13876, 2023.

[101] T. Pham, T. Tran, D. Phung, and S. Venkatesh, "Predicting healthcare trajectories from medical records: A deep learning approach," *J. Biomed. Inform.*, vol. 69, pp. 218–229, May 2017.

[102] M. G. Poirot, P. Vepakomma, K. Chang, J. Kalpathy-Cramer, R. Gupta, and R. Raskar, "Split Learning for collaborative deep learning in healthcare," *arXiv [cs.LG]*, 27-Dec-2019.

[103] A. S. W. Chan, J. M. C. Ho, and P. M. K. Tang, "Cancer and the LGBT Community: Cancer and the LGBT Community (2015th

ed.), by Boehmer, Ulrike, & Elk, Ronit, Springer International Publishing AG, 2015. https …," 2021.

[104] G. Virone, A. Wood, L. Selavo, and Q. Cao, "An advanced wireless sensor network for health monitoring," *home healthcare …*, 2006.

[105] A. S. W. Chan and P. M. K. Tang, "Application of Novel Psychoactive Substances: Chemsex and HIV/AIDS Policies Among Men Who Have Sex With Men in Hong Kong," *Front. Psychiatry*, vol. 12, p. 680252, Jul. 2021.

[106] A. Vozikis, A. Panagiotou, and S. Karakolias, "A Tool for Litigation Risk Analysis for Medical Liability Cases," *HAPScPBS*, vol. 2, no. 2, pp. 268–277, Dec. 2021.

[107] N. Polyzos *et al.*, "Greek National E-Prescribing System: Preliminary Results of a Tool for Rationalizing Pharmaceutical Use and Cost," *Glob. J. Health Sci.*, vol. 8, no. 10, p. 55711, Oct. 2016.

[108] S. Karakolias and N. Polyzos, "Application and assessment of a financial distress projection model in private general clinics," *Archives of Hellenic Medicine/Arheia Ellenikes Iatrikes*, vol. 32, no. 4, 2015.

[109] S. Karakolias, C. Kastanioti, M. Theodorou, and N. Polyzos, "Primary care doctors' assessment of and preferences on their remuneration," *Inquiry*, vol. 54, p. 46958017692274, Jan. 2017.

[110] S. E. Karakolias and N. M. Polyzos, "The newly established unified healthcare fund (EOPYY): current situation and proposed structural changes, towards an upgraded model of primary health care, in Greece," *Health* , vol. 2014, 2014.

[111] S. K. Pandey and R. R. Janghel, "Recent Deep Learning Techniques, Challenges and Its Applications for Medical Healthcare System: A Review," *Neural Process. Letters*, vol. 50, no. 2, pp. 1907–1935, Oct. 2019.

[112] M. Jorge Cardoso *et al.*, "MONAI: An open-source framework for deep learning in healthcare," *arXiv [cs.LG]*, 04-Nov-2022.